Alnylam Pharmaceuticals (NASDAQ: ALNY) net income
Alnylam Pharmaceuticals reported a net profit of $313.7m for fiscal 2025; in fiscal 2024 it reported a net loss of $278.2m. Its net margin was 8.4%. Earnings per share were $2.39.
Fiscal 2025 is the highest of the 10 fiscal years on record for Alnylam Pharmaceuticals. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $313.7m | — | 8.4% | $2.39 |
| 2024 | −$278.2m | — | −12.4% | −$2.18 |
| 2023 | −$440.2m | — | −24.1% | −$3.52 |
| 2022 | −$1,131m | — | −109.0% | −$9.30 |
| 2021 | −$852.8m | — | −101.0% | −$7.20 |
| 2020 | −$858.3m | — | −174.1% | −$7.46 |
| 2019 | −$886.1m | — | −403.2% | −$8.11 |
| 2018 | −$761.5m | — | −1,016.6% | — |
| 2017 | −$490.9m | — | −545.9% | — |
| 2016 | −$410.1m | — | −869.6% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Alnylam Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Alnylam Pharmaceuticals ranks 74th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Alnylam Pharmaceuticals, 8.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 72nd | Ensign Group | $344.0m | 6.8% |
| 73rd | Halozyme Therapeutics | $316.9m | 22.7% |
| 74th | Alnylam Pharmaceuticals | $313.7m | 8.4% |
| 75th | Aurinia Pharmaceuticals | $287.2m | 101.5% |
| 76th | BeOne Medicines | $286.9m | 5.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Alnylam Pharmaceuticals
- How much did Alnylam Pharmaceuticals earn in fiscal 2025?
- Alnylam Pharmaceuticals reported a net profit of $313.7m for fiscal 2025. In fiscal 2024 it reported a net loss of $278.2m.
- What are the earnings per share of Alnylam Pharmaceuticals?
- They were $2.39 in fiscal 2025, compared with −$2.18 in fiscal 2024.
- What is the net margin of Alnylam Pharmaceuticals?
- In fiscal 2025 its net profit was 8.4% of its revenue.
- What was the most profitable year for Alnylam Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $313.7m.
- Where does Alnylam Pharmaceuticals rank in its sector by net income?
- It ranks 74th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Alnylam Pharmaceuticals come from?
- From the annual report (Form 10-K) that Alnylam Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Alnylam Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Alnylam Pharmaceuticals: the Alnylam Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.